Request Your Free White Paper Now:

"The Critical Role of NGS Reference Materials in Precision Oncology Applications"

Cancers can be caused by a multitude of distinct genetic abnormalities, and each tumor is unique. Dozens of new targeted therapies have been developed in recent years, but the challenge of providing optimal care to cancer patients lies in the ability to match the genetic profile of the tumor to the most appropriate therapy.

Advances in next-generation sequencing (NGS) technologies have enhanced the identification of hundreds of mutations that may contribute to disease progression, and the development of new diagnostic NGS assays is continually evolving. These assays can profile genetic mutations to enable precision diagnostics, personalized treatment selection, stratification of patients for clinical trials, and improved disease monitoring.

This white paper from LGC SeraCare describes the role reference materials play in developing and validating robust precision oncology assays that can perform with the accuracy, sensitivity, and reproducibility required for clinical use, as well as considerations for selecting the most appropriate provider of reference materials.

Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences